Recombinant human tumor necrosis factor-o~ (TNF-c~) has demonstrable antitumor activity in transplantable murine tumor models and patients with cancer but is highly toxic to both animals and human beings. The narrow therapeutic index of TNF-cx has limited its anticancer utility. Toxicity associated with many standard anticancer drugs is highly dependent upon the circadian timing of their administration. The effect of time of day of TNF-o~ administration on lethal toxicity was examined in 238 BALB/c female mice in two studies. Each mouse received a single intravenous injection of human TNF-c~ at one of six equispaced times within the first contiguous 24-h cycle. The probability of dying across all times of day of TNF-c~ treatment was not equal (p <0.01) and varied up to ninefold. Significant time of day dependence of TNF-cx toxicity was present over a full order of magnitude of TNF-ot dose. The frequency of TNF-a-induced lethality was greatest and the time to death was most brief when TNF-a was administered just before awakening. The survival probability was highest when TNF-o~ was administered in the second half of the daily activity span corresponding roughly to late afternoon and evening hours for human beings. The optimization of TNF-c~ administration timing is a strategy that warrants further investigation for improving the toxic/therapeutic ratio of this important cytokine. From a more fundamental perspective, these data may be essential for achieving a fuller understanding of TNF-o~ in vivo biology.
Sul-lrlmary
Recombinant human tumor necrosis factor-o~ (TNF-c~) has demonstrable antitumor activity in transplantable murine tumor models and patients with cancer but is highly toxic to both animals and human beings. The narrow therapeutic index of TNF-cx has limited its anticancer utility. Toxicity associated with many standard anticancer drugs is highly dependent upon the circadian timing of their administration. The effect of time of day of TNF-o~ administration on lethal toxicity was examined in 238 BALB/c female mice in two studies. Each mouse received a single intravenous injection of human TNF-c~ at one of six equispaced times within the first contiguous 24-h cycle. The probability of dying across all times of day of TNF-c~ treatment was not equal (p <0.01) and varied up to ninefold. Significant time of day dependence of TNF-cx toxicity was present over a full order of magnitude of TNF-ot dose. The frequency of TNF-a-induced lethality was greatest and the time to death was most brief when TNF-a was administered just before awakening. The survival probability was highest when TNF-o~ was administered in the second half of the daily activity span corresponding roughly to late afternoon and evening hours for human beings. The optimization of TNF-c~ administration timing is a strategy that warrants further investigation for improving the toxic/therapeutic ratio of this important cytokine. From a more fundamental perspective, these data may be essential for achieving a fuller understanding of TNF-o~ in vivo biology.
T
NF-ot has emerged as an important regulator of inflammation being one of the mediators of acute phase reactions, endotoxic shock, cachexia of chronic disease states, and ceU-mediated host defense against bacteria, parasites, and tumor cells (1, 2) . TNF-ol induces hemorrhagic necrosis and regression of a variety of transplantable murine and human tumors (3) (4) (5) . The mechanisms responsible for the antitumor action of TNF-ol include both direct toxic effects upon tumor cells (6) , indirect host-mediated procoagulant (7) , and immunomodulatory effects which require host immune competency (4) .
Therapeutically, recombinant human TNF-c~ has been investigated as a potential anticancer agent over the last decade for the treatment of patients with advanced cancer. Phase I clinical studies in cancer patients have, however, been daunting because of the severity of TNF-c~ toxicity (8) (9) (10) . The endotoxin-like toxicities uniformly include hemodynamic instability, fever, diarrhea, metabdic acidosis, capillary leak syndrome, induction of a catabolic state, neurotoxicity, and renal and hematologic toxocity which severely limit drug dosing. At the same time, responses have been very infrequent with only minimal or partial responses observed.
These experimental and clinical data demonstrate that TNF-c~ can act either as a therapeutic tool or as a lethal toxic agent (11, 12) . The narrow therapeutic index of TNF-o~ has encouraged the development of strategies to diminish toxicity while hopefully preserving antitumor activity. Several approaches include use of continuous infusions (13) , glucocorticoids (14) , inhibitors of prostaglandin synthesis (15) , scavengers of oxygen radicals (16) , and combining TNF-ot with cytotoxic chemotherapy (17) or other cytokines (18) . Toxicity still remains the most significant limitation to TNF-c~ therapeutic utility.
The toxicity of many standard cytotoxins in animals and humans can be reduced and dose intensity increased by appropriate circadian timing (19) . In animal studies, optimal circadian drug timing has consistently been associated with maintenance of antitumor activity and has often improved tumor responses (20) . In view of these findings and the realization that few, if any, biological processes do not participate in high-amplitude circadian rhythms, we examined the effect of circadian timing of TNF-o~ administration on lethal toxicity in BALB/c mice. Toxicity Study Design. Two large studies each involving the investigation of six groups of female BALB/c mice treated at one of six times spaced by 4-h intervals during the initial 24-h span were performed. In Study 1, a total of 119 mice were studied. Each of the six circadian treatment groups were randomly divided into four subgroups of five animals each (except for the 06 HALO group with 10 MU/kg, 4 mice were injected). Each subgroup received one of four randomly assigned doses of TNF-ot (3.3, 6.7, 10.0, or 13.3 MU/kg). In Study 2, a total of 119 mice were studied. Each of the six circadian treatment groups was randomly divided into two subgroups of 10 animals each (except for the 02 HALO group with 27.0 MU/kg, nine mice were injected). Each subgroup received one of two doses of TNF<z (18.0 or 27.0 MU/kg). The final number of animal deaths per group (percent mortality) and the time to death (hours) after TNF-ot injection of each animal (survival time) was recorded. Toxicity was assessed by inspecting cages every 2 h for animal deaths for up to 4 d. Proportional survival analyses were performed with data truncated at the time of last toxic death (98 h for Study 1 and 62 h for Study 2).
Statistical Analysis. For each study, the proportion of animals dead in each subgroup was compared by chi squared (X 2) analysis.
The percent survivors as a function of either dose or treatment timing was also evaluated by Kruskall-Wallis (KW) life table analysis. Analyses of variance (ANOVA, F value) were employed to determined the effects of TNF-ot dose and circadian time of TNFot injection upon survival time. The presence of circadian (sinusoidal) rhythm was assessed for the proportion of the treatment groups surviving and for the survival times by the cosinor least squares methods. (21) .
LDso. The lethal dose for 50% mortality (LD50, dose of TNF-ot that kills 50% of animals) is calculated by treating groups of animals with different doses across a range of doses that kills from a small minority of the exposed animals to well over half of them. Equal groups of the 238 mice in our study were treated with 1 Abbreviations used in this paper: ANOVA, analysis of variance; HALO, hours after light onset; KW, Kruskall-Wallis; MU, Million units. one of six TNF doses covering an order of magnitude of TNF-o~ (from ,,o3 to '-30 MU/kg) and at each of six equispaced times of day. To determine the relationship between dose and lethality, the mortality achieved at each dose was plotted against that dose and a line was fit by the process of least squares. This process was repeated for all dose groups treated at each of the six times of day yielding six separate lethality relationships with correlation coefficients (R) and six LD50 estimates. Linear regression of data grouped from treatments during sleep phase versus treatment during activity phase were also performed for calculation of LD50 of these grouped data.
Results

Toxicity Studies
Survival Time Analysis. Time to death (survival time) truncated at the moment of last toxic death in each study was analyzed for dose and time of day effects. The mean survival times of these mice depend both upon the time of day of TNF-ot administration, and upon the dose of TNF-cz administered. As expected, the greater the TNF-ot dose the shorter the survival time. A two-way ANOVA of the truncated survival time of mice treated with different TNF-ot doses from each study separately and from both studies combined demonstrates a significant circadian time effect (Fig. 1 A, F = 7.1, p = 0.0001) as well as significant TNF-ot dose-effect ( Fig. 1 B, F = 51.4, p = 0.0001). An interaction between these two factors was also prominent (F = 2.5, p <0.001), demonstrating that dose and timing have complex relations to mortality; e.g., lower doses at some times of day have greater lethality than much higher doses at other times of day. The mean truncated survival time of mice injected during the sleep span (02, 06, and 10 HALO) is much lower (43 h versus 68 h) than when the agent is given during the activity span (14, 18, and 22 HALO). The toxicity of TNF-ot is greatest at 06 and 10 HALO (sleep phase) as evidenced by shorter survival times than at 14 and 18 HALO (late activity phase). Regardless of dose, time of day of TNF-ot treatment was responsible for a 1.5-2-fold variation in survival times. The optimal times would approximate late afternoon and early evening for a diurnally active human being.
Analysis of Final Proportional Survival. Percent overall mor-
tality as a function of the time of day mice received TNF-cz and the dose of TNF-ot was analyzed by X 2 analyses for each study (Table 1) . In Study 1, overall mortality ranged from 10 to 38% for all TNF-ot doses. A significant circadian treatment time effect (X z = 15.8, p = 0.008) was demonstrated for the frequency of final overall mortality across all doses of TNF-ot. The most statistically significant circadian timedependent toxicity (X 2 --19.0, p ---0.002) was seen at 10.0 MU/kg dose of TNF-ot, where 100% of the mice died when treated just before daily awakening (10 HALO). This is contrasted to a total lack of mortality when mice receive the same dose of TNF-ot during the middle of the activity span (18 HALO) . Across all doses, mice treated during the second half of their daily activity phase (18 HALO) died less frequently (10% mortality), whereas mice treated just before awakening (10 HALO) showed a much higher final lethality (55% mor- Fig. 2 A) and the 27.0 MU/kg dose (KW score = 17.4, p <0.05, Fig. 2 B) . At both doses, mice treated in the middle and second half of the daily sleep span (06-10 HALO) died earlier and more frequently than those mice treated in the activity span (14-22 HALO). Proportional survival truncated when 50% of animals have died is an alternative way to look at time-dependent mortality. Since >50% mortality was achieved only in the Study 2, mortality truncated at 50% overall mortality was analyzed for this study (Table 1) . Mice injected during the activity span (14-22 HALO) showed two to threefold lower mortality than those injected during the sleep span (02-10 HALO) assessed by percent mortality. The highest mortality of TNF-ot was observed when administered at 06 HALO (95%) and the lowest mortality was seen when TNF-c~ was administered at 22 HALO (25%). The pattern and magnitude of these results are in accord with the LDso calculations derived above.
LDso Analysis and Mortality
Circadian Rhythm Analysis
Cosinor least squares analysis of a 24-h period fit was performed on the truncated survival time of TNF-ot-treated mice ( Table 2 ). In Study 1, a significant 24-h rhythm in TNF-ot toxicity was found when all doses were examined together (p = 0.052). Across all doses, the time of day of treatment predicted for maximal survival (acrophase) is at end of the activity span (21:19 HALO) . This same time of day was consistently found for each of the larger TNF-ot doses. The lowest TNF-ot dose (3.3 MU/kg), which killed only a tenth of the mice, predicted a somewhat different time of day for maximum survival time in the late sleep span (10:00). For Study 2, where overall mortality consistently exceeded 50%, a significant 24-h rhythm of TNF-ot toxicity was also found (p <0.001). The predicted time of day for maximum survival (acrophase) was also found in mid-to-late activity (17:52 HALO). In both studies, the amplitude of the 24-h TNF-oe toxicity rhythm was greater with higher doses of TNF-ot, implying a greater proportion of the variability in toxicity was attributable to time of day-dependent differences. These analyses indicate that the safest time for TNF-ot may be midto-late in the daily activity span, a time comparable to 4-10 p.m. for diurnally active human beings.
Discussion
At the end of last century, the medical community began paying attention to the therapeutic approach of Coley (22) Cosinor analysis was performed with a 24-h period fit. * Mesor, 24-h adjusted mean for the survival time (h). * Amplitude, half the difference between maximal and minimal values for survival time.
S Acrophase, time of day expressed in HALO for the maximum predicted survival time that was most consistently between 17:00 and 22:00 HALO (mid to late sleep). Values are given with the standard error.
bacterial cultures. Later, the immune and inflammatory reactions, known as the Shwartzman phenomenon, associated with bacterial toxin administration, were observed to be associated with local and sometimes generalizable anticancer effects (23, 24) . A tenacious search for the factors responsible for the tumor hemorrhage associated with the administration of these toxins concluded with the identification and isolation of endotoxins. Associated with these toxin exposures was the release of a series of powerful cytokines. TNF-ot was finally identified as a prominent component of this inflammatory process (25, 26) . It was found that TNF-cz could reproducibly cause shrinkage of and even cure transplantable, chemically induced cancers (meth-A sarcoma) in BALB/c mice (27) . The therapeutic responses in animals and humans, however, have usually been achieved at doses of TNF-ot approaching those associated with endotoxin-induced shock (2, 11, 12) . We have found that the timing within the day of TNF-ot administration to BALB/c mice is responsible for up to a ninefold difference in the frequency of lethal toxicity and time to death over a range of TNF-ot doses. As the dose of TNF-ot increased, the time of day difference in this predictable toxicity rhythm becomes greater. In light of the central importance of TNF-ot in mediating endotoxin-induced lethality, it is interesting to note a circadian-timed endotoxin study done more than 30 yr ago. Halberg et al. (28) reported that the susceptibility of mice to Escherichia coli endotoxin-induced lethality varied significantly and predictably throughout the day. When endotoxin was administered during the activity span, a 10-fold-lower mortality of BALB/c mice reproducibly occurred. This finding accurately predicts and is coincident with the circadian toxicity pattern for TNF-tx demonstrated here. In D-galactosamine-loaded mice (to enhance endotoxin susceptibility), a ninefold difference in the susceptibility to endotoxin or monophosphoryl lipid A-induced lethal toxicity was seen with greatest toxicity when the agents were administered at the sleep-wake border (29) . The diurnal variation in endotoxin toxicity reported with D-galactosamineloaded mice was paralleled by circadian-dependent elevations in serum TNF-a levels.
TNF-t~ is clearly a final common pathway for the induction of endotoxin-associated shock secondary to sepsis. It is interesting to note that hospital deaths, many associated with sepsis, do not occur randomly throughout the day but are more frequent between 2 a.m. and 6 a.m. (30) . This time of day corresponds to the time in the circadian cycle when endotoxin and TNF<x are each most frequently lethal. The recognition and explanation of this time structure may well be helpful to the successful use of the many potential molecular blockers of sepsis-induced lethality that are currently under aggressive clinical study.
The underlying mechanisms for this time of day toxicity are not known. The peak toxicity for TNF-ot and E. coli endotoxin both occur at the time of day that is close to the usual daily cortisol peak (31) . Very large and reproducible circadian-dependent variations in the production and secretion of glucocorticoids, adrenocorticotropic hormone and growth hormone have been documented. These same hormones are also important in mediating the response to acute infectious and endotoxic challenge. Pharmacological manipulation of glucocorticoid levels can influence the response to TNF-ot and endotoxin. Treatment of ceils in vitro with high doses of glucocorticoid can modulate the production of several inflammatory cytokines including TNF-t~ (32), ILl (33), IFN-3, (34), and IL-2 (35) . Adrenalectomy has been reported to sensitize mice to the lethal response to endotoxin (36, 37) . Endotoxin causes increased glucocorticoid production and mice rendered tolerant to TNF in vivo have increased glucocorticoid production. However, in normal animals, glucocorti-1063 Hrushesky et al.
coid receptor antagonists did not prevent endotoxin effects (38) . How well these extreme manipulations of glucocorticolds relate to the endogenous circadian change in glucocorticoid levels is not clear. Hypophysectomy can increase the sensitivity to lethality of bacterial inoculation (39) and pituitary-hypophyseal-derived proteins appear to modulate this response. Growth hormone protects hypophysectomized mice from lethal bacterial challenge (39) , whereas pituitary production of macrophage migration inhibitory factor (MIF) or administration of MIF enhances the lethality of endotoxin (40) . Serum levels oflL-1 vary throughout the day (41) which could conceivably modulate TNF effects and cytokine cascades. Mechanisms by which the normal physiologic circadian variation in the production of these hormones and their response to physiologic modulation contributes to circadiandependent lethality of TNF and endotoxin warrant investigation.
Other mechanisms may also contribute to circadiandependent differences in TNF-oe-induced lethality. Daily variations in the function of target tissues exist and could modulate the susceptibility of these tissues to TNF-ot-mediated toxicity. For example, circadian-dependent variations in the glutathione cycle activity (20) , in immune cell function (42) , bone marrow function (43) , and tumor blood flow (44) , have all been described. Time of day-dependent differences in protein drug pharmacokinetics may also contribute to time of day toxicity profiles.
Circadian timing of drug administration, as a strategy to alter dose-limiting toxicities, has been demonstrated in preclinical and clinical studies with traditional agents. Circadian timing of antitumor or hematopoietic cytokines may be an additional strategy to alter dose-limiting toxicities and/or improve efficacy. The circadian time structure of therapeutic cytokine administration is beginning to be investigated. Myelotoxicity and antitumor activity of IFN-oe and IFN-3' have been demonstrated to vary as a function of circadian time of administration in mice (45) (46) (47) . The optimal time for minimal myelotoxicity and maximal antitumor activity were coincident for each type of IFN but with different optimal times of day for the two classes of IFNs. Hematopoietic growth factor efficacy also varies with the time of day of their administration (48) . Our current studies suggest that TNF-oe toxicity is highly dependent upon the time of day of administration. Optimal circadian timing of TNF-oe administration might be a useful strategy to consider to increase dose intensity and possibly enhance antitumor efficacy.
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